4.92
+0.61%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Faes Farma
Its shares trade on BME under the ticker FAE.MC. It has been listed since 25 March 1994. In the fiscal year to 31 December 2025, it reported revenue of €610.5m and net income of €79.6m. At that date it held total assets of €1.34bn and shareholders' equity of €744.8m.
Faes Farma SA is a pharmaceutical company. The company is headquartered in Madrid, Madrid. The firm specializes in the research, production, distribution and sale of prescription and generic drugs, over-the-counter (OTC) medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The Company’s research lines are mainly focused on the development of new drugs for the treatment of allergy, venous insufficiency and irritable bowel syndrome, among others. In addition, it provides animal nutrition products. The firm operates in Spain, Portugal, Chile and Mexico, among others. The company controls a number of subsidiaries, such as Laboratorios Vitoria SA, Laboratorios Veris SA, Lazlo International SA, Ingaso Farm SLU, Esfion SA and Biotecnet I MAS D SA.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 25 Mar 1994
- Employees
- 1,440
- Website
- faesfarma.com ↗
Leadership
Pay as last reported
- Don Mariano Ucar AnguloChairman of the Board, Other External Director, since 1991€3.3m
- Don Eduardo Recoder De La CuadraChief Executive Officer, Executive Director, since 2024€526,000
- Don Valentin Ruiz UnamunzagaChief Financial Officer, since 2024
- Don Carlos Gutierrez AgueroChief People Officer
- Don Jaime LopezGlobal Head - IT
- Don Alberto Fernandez FernandezChief Marketing and Portfolio Strategy Officer
- Dna. Isabel NajeraChief Scientific and Medical Officer
- Dna. Mariana Soroa ZubiriaChief GRC & Internal Audit Officer, since 2024
- Dna. Maria MarinHead - Investor Relations & External Comms
- Don Xavier ArnaudChief Business Development Officer
- Don Helder CassisCountry Manager, Portugal, since 2024
- Don Jose Luis Diaz CapoteChief International Business Officer, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 65
- Environment
- 66
- Social
- 99
- Governance
- 31
- Direct emissions (scope 1)
- 4,965 t
- Energy emissions (scope 2)
- 2,615 t
- Women in the workforce
- 54%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong brand reputation: Faes Farma SA has established itself as a reputable pharmaceutical company.
- Diverse product portfolio: The company offers a wide range of pharmaceutical products, catering to various medical needs.
- Technological innovation: Faes Farma SA invests in research and development to develop advanced healthcare solutions.
Weaknesses
- Dependence on specific markets: The company's revenue heavily relies on specific geographical areas, making it vulnerable to market fluctuations.
- Limited international presence: Faes Farma SA has a limited global reach compared to its competitors.
- Higher production costs: The company faces challenges in maintaining cost-effectiveness due to higher production costs compared to some competitors.
Opportunities
- Emerging markets: Faes Farma SA can expand its presence in growing markets, such as Asia and Latin America, to increase its market share.
- Growing demand for personalized medicine: The company can capitalize on the increasing demand for customized healthcare solutions by developing personalized medicines.
- Strategic partnerships: Faes Farma SA can form alliances with other pharmaceutical companies or healthcare providers to enhance its distribution network and access new markets.
Threats
- Intense competition: The pharmaceutical industry is highly competitive, with numerous players vying for market share.
- Stringent regulations: Compliance with stringent regulatory requirements can pose challenges for Faes Farma SA, affecting its product development timelines and profitability.
- Economic uncertainty: Fluctuations in the global economy can impact consumer spending on healthcare products and affect the company's financial performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.